Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (7): 829-834.doi: 10.12092/j.issn.1009-2501.2020.07.017

Previous Articles     Next Articles

Research progress on roles of gut microbiota in cardiovascular disease and treatment

YAN Yu 1, LIU Kang 2, LIAN Wenwen 1, ZHANG Zhen 1, HE Jun 1   

  1. 1 China-Japan Friendship Hospital, Beijing 100029, China; 2 Electric Power Teaching Hospital, Capital Medical University, Beijing 100073, China
  • Received:2020-04-08 Revised:2020-05-28 Online:2020-07-26 Published:2020-07-31
  • Contact: 赫军,男,博士,副主任药师,研究方向:中药活性成分的发现和新药开发。 Tel: 15010297582 E-mail: 15010297582@126.com

Abstract: Cardiovascular disease (CVD), a chronic disease endangering human health, remains the highest morbidity and mortality globally. The human gut is inhabited by communities of bacteria and viruses, along with their genome, are collectively known as the gut microbiota. Recent reserch suggests that gut microbiota affects various metabolic pathways in the host by producing and releasing important metabolites such as trimethylamine oxide, bile acids and short chain fatty acids, and play an important role in pathologies of CVD, such as atherosclerosis, hypertension, myocardial infarction, heart failure and dyslipidemia. Individual treatment based on gut microbiota, including diet intervention, fecal microbiota transplantation and small molecule antimicrobial enzyme therapeutics, may provide a potential novel strategy for therapeutics.

Key words: cardiovascular disease, gut microbiota, individual treatment, therapeutic strategy

CLC Number: